FIG 1.

Patient flow diagram. (*) One patient of the cohort received chemotherapy with temozolomide and a combination of procarbazine, lomustine, and vincristine (PCV) for progressing oligodendroglioma 5 years and 10 months after his NS relapse; because his first relapse was pure teratoma and was treated with surgery alone, because of the long GCC-free interval until initiation of chemotherapy for his second malignancy, and because none of the other patients with pure teratoma relapses experienced a subsequent relapse, it was decided not to exclude this patient from data analysis. (†) Death from oligodendroglioma. (‡) Patient died of sepsis, bleeding, and respiratory insufficiency during high-dose chemotherapy with carboplatin/etoposide.